Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anika TherapeuticsSTU:AKP +2.20%66 Days Inventory is 206.04 as of Jun. 2026, which is 16% below its 10-year median of 243.85. GuruFocus rates STU:AKP with a GF Score™ of 66/100 and a GF Value™ of €16.73 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Anika Therapeutics ranks worse than 50.43% on this metric.
The historical rank and industry rank for Anika Therapeutics's Days Inventory or its related term are showing as below:
STU:AKP'
s Days Inventory Range Over the Past 10 Years
Min: 158.61 Med: 243.85 Max: 340.56
Current: 165.34
During the past 13 years, Anika Therapeutics's highest Days Inventory was 340.56. The lowest was 158.61. And the median was 243.85.
STU:AKP's Days Inventory is ranked worse than 50.43% of 920
companies
in the Drug Manufacturers industry
Industry Median: 164.815
vs STU:AKP: 165.34
Anika Therapeutics's Days Inventory
increased
from Jun. 2025 (130.68) to Jun. 2026 (206.04).
It might indicate that Anika Therapeutics's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Anika Therapeutics's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Anika Therapeutics's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.79.
Anika Therapeutics (STU:AKP) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Anika Therapeutics's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Anika Therapeutics's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Anika Therapeutics Days Inventory Related Terms
Anika Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Anika Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AKP vs SIGA, DERM, LFCR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anika Therapeutics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Anika Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anika Therapeutics (STU:AKP) has a Days Inventory of 206.04 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Anika Therapeutics and its competitors. This is 16% below median its historical median of 243.85. Over the past decade, Anika Therapeutics' Days Inventory has ranged from 158.61 to 340.56. According to the industry distribution chart, Anika Therapeutics ranks #464 out of 920 companies in the Drug Manufacturers industry, placing it in the top 50.4%.
Is Anika Therapeutics' Days Inventory too high?
Anika Therapeutics' current Days Inventory of 206.04 is 16% below median its 10-year median of 243.85. Over the past 10 years, this metric has ranged from a low of 158.61 to a high of 340.56. The Drug Manufacturers industry median Days Inventory is 164.82. Anika Therapeutics' value of 206.04 is 25% above this industry median. Based on the distribution chart, Anika Therapeutics ranks #464 out of 920 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anika Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Days Inventory compare to SIGA and DERM?
According to the Drug Manufacturers industry distribution chart, Anika Therapeutics ranks #464 out of 920 companies for Days Inventory. This places Anika Therapeutics in the lower half of its industry. The industry median Days Inventory is 164.82. Anika Therapeutics' value of 206.04 is 25% above this benchmark. Historically, Anika Therapeutics' own Days Inventory has ranged from 158.61 to 340.56 over the past decade. While the company's 10-year median is 243.85 vs. the industry median of 164.82, Anika Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.82, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anika Therapeutics's current Days Inventory of 206.04 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Anika Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anika Therapeutics's current Days Inventory is 206.04, which is 16% below median its own 10-year median of 243.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Overvalued. The stock's GF Value™ is €16.73, compared to a current price of €18.60 — trading 11.2% above its estimated fair value. The current Days Inventory is 206.04, which is 16% below median its 10-year median of 243.85 and 25% above the Drug Manufacturers industry median of 164.82. Anika Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Days Inventory is 206.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anika Therapeutics (STU:AKP) Overvalued in 2026?
Based on GuruFocus' analysis, Anika Therapeutics stock appears to be overvalued.
The current stock price of €18.60 is trading 11.2% above its estimated GF Value™ of €16.73.
GuruFocus considers Anika Therapeutics to be Modestly Overvalued.
Key valuation signals for STU:AKP:
Days Inventory: 206.04 (16% below median its 10-year median of 243.85)
GF Value™: €16.73 vs. price of €18.60 (11.2% above fair value)
Industry Position: 25% above the Drug Manufacturers median (#464 of 920)
No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
66GF Score
Get the complete analysis for STU:AKP
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AKP has been successfully added to your 
